Mabvax Therapeutics Holdings Inc Stock Other OTC
Equities
US55414P1084
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
Financials (USD)
Sales 2016 | 148K | Sales 2017 | - | Capitalization | 14.41M |
---|---|---|---|---|---|
Net income 2016 | -17M | Net income 2017 | -19M | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K | Net Debt 2017 | 2.48M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 14-07-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |